Sign Out
The maximum amount of recombinant human erythropoietin that can be safely administered in single or multiple doses has not been determined. The response to erythropoietin administration is individual and dose-related.
Therapy with recombinant human erythropoietin may result in polycythemia if the hematocrit is not carefully controlled and the dose is not adjusted. If the target range is exceeded, recombinant human erythropoietin may be discontinued temporarily until the hematocrit return to the target range; then the therapy with recombinant human erythropoietin may be resumed using a lower dose (see Dosage & Administration).
Precautions: Hypertension and seizures. If polycythemia is a concern, phlebotomy in order to reduce the hematocrit may be started.
